-
Something wrong with this record ?
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT
L. Sellner, A. Boumendil, H. Finel, S. Choquet, G. de Rosa, F. Falzetti, R. Scime, G. Kobbe, F. Ferrara, A. Delmer, H. Sayer, S. Amorim, R. Bouabdallah, J. Finke, G. Salles, I. Yakoub-Agha, E. Faber, E. Nicolas-Virelizier, L. Facchini, D....
Language English Country England, Great Britain
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1997 to 1 year ago
Freely Accessible Science Journals
from 1997 to 1 year ago
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
PubMed
26569093
DOI
10.1038/bmt.2015.273
Knihovny.cz E-resources
- MeSH
- Autografts MeSH
- Cytarabine administration & dosage MeSH
- Adult MeSH
- Carmustine administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphoma mortality therapy MeSH
- Melphalan administration & dosage MeSH
- Survival Rate MeSH
- Adolescent MeSH
- Podophyllotoxin administration & dosage MeSH
- Disease-Free Survival MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage MeSH
- Registries * MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Thiotepa administration & dosage MeSH
- Stem Cell Transplantation * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.
APHP Hopital Saint louis Hemato Oncology Paris Diderot University Sorbonne Paris Cité Paris France
Cardarelli Hospital Napoli Italy
Department of Hematology and Oncology Helios Hospital Erfurt Erfurt Germany
Department of Hematology Azienda Ospedali Riuniti Villa Sofia Cervello Palermo Italy
Department of Hematology Freiburg University Medical Center Freiburg Germany
Department of Hematology Pitié Salpêtrière Hospital Paris France
Department of Medicine 5 University Hospital Heidelberg Heidelberg Germany
Hematologie Hospices Civils de Lyon and Université Claude Bernard Lyon 1 Pierre Bénite France
Hematology Department Centre Leon Berard Lyon France
Hematology Department Paoli Calmettes Institute Marseille Aix Marseille University Marseille France
Hematology Unit Arcispedale S Maria Nuova IRCCS Reggio Emilia Italy
Hematology Unit Ospedale Civile Piacenza Italy
Hematology Unit S Maria delle Croci Hospital Ravenna Italy
Lymphoma Working Party European Society for Blood and Marrow Transplantation Paris France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17000873
- 003
- CZ-PrNML
- 005
- 20170112123719.0
- 007
- ta
- 008
- 170103s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/bmt.2015.273 $2 doi
- 024 7_
- $a 10.1038/bmt.2015.273 $2 doi
- 035 __
- $a (PubMed)26569093
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Sellner, L $u Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
- 245 10
- $a Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT / $c L. Sellner, A. Boumendil, H. Finel, S. Choquet, G. de Rosa, F. Falzetti, R. Scime, G. Kobbe, F. Ferrara, A. Delmer, H. Sayer, S. Amorim, R. Bouabdallah, J. Finke, G. Salles, I. Yakoub-Agha, E. Faber, E. Nicolas-Virelizier, L. Facchini, D. Vallisa, E. Zuffa, A. Sureda, P. Dreger, . ,
- 520 9_
- $a Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
- 650 _2
- $a autologní štěp $7 D064592
- 650 _2
- $a karmustin $x aplikace a dávkování $7 D002330
- 650 _2
- $a cytarabin $x aplikace a dávkování $7 D003561
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfom $x mortalita $x terapie $7 D008223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melfalan $x aplikace a dávkování $7 D008558
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a podofylotoxin $x aplikace a dávkování $7 D011034
- 650 12
- $a registrace $7 D012042
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a transplantace kmenových buněk $7 D033581
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a thiotepa $x aplikace a dávkování $7 D013852
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Boumendil, A $u Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France.
- 700 1_
- $a Finel, H $u Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France.
- 700 1_
- $a Choquet, S $u Department of Hematology, Pitié-Salpêtrière Hospital, Paris, France.
- 700 1_
- $a de Rosa, G $u University of Napoli, Napoli, Italy.
- 700 1_
- $a Falzetti, F $u University of Perugia, Perugia, Italy.
- 700 1_
- $a Scime, R $u Department of Hematology, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
- 700 1_
- $a Kobbe, G $u University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
- 700 1_
- $a Ferrara, F $u Cardarelli Hospital, Napoli, Italy.
- 700 1_
- $a Delmer, A $u Service d'Hématologie Clinique, Hôpital Robert Debré, Centre Hospitalier Universitaire (CHU) de Reims, Reims, France.
- 700 1_
- $a Sayer, H $u Department of Hematology and Oncology, Helios Hospital Erfurt, Erfurt, Germany.
- 700 1_
- $a Amorim, S $u APHP, Hopital Saint-louis, Hemato-Oncology Paris Diderot University, Sorbonne Paris Cité, Paris, France. $7 gn_A_00005720
- 700 1_
- $a Bouabdallah, R $u Hematology Department, Paoli Calmettes Institute, Marseille Aix-Marseille University, Marseille, France.
- 700 1_
- $a Finke, J $u Department of Hematology, Freiburg University Medical Center, Freiburg, Germany.
- 700 1_
- $a Salles, G $u Hematologie, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre Bénite, France.
- 700 1_
- $a Yakoub-Agha, I $u LIRIC-U995, Hematology Department and Hematopoietic Stem Cell Transplantation Unit, University-Hospital of Lille, Lille, France.
- 700 1_
- $a Faber, E $u Department of Hemato-Oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Nicolas-Virelizier, E $u Hematology Department, Centre Leon Berard, Lyon, France.
- 700 1_
- $a Facchini, L $u Hematology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy.
- 700 1_
- $a Vallisa, D $u Hematology Unit, Ospedale Civile, Piacenza, Italy.
- 700 1_
- $a Zuffa, E $u Hematology Unit, S Maria delle Croci Hospital, Ravenna, Italy.
- 700 1_
- $a Sureda, A $u Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France. Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
- 700 1_
- $a Dreger, P $u Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany. Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France.
- 700 1_
- $a ,
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 51, č. 2 (2016), s. 212-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26569093 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170103 $b ABA008
- 991 __
- $a 20170112123819 $b ABA008
- 999 __
- $a ok $b bmc $g 1180013 $s 961440
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 51 $c 2 $d 212-8 $e 20151116 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20170103
